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Zone of inhibitionAbstract A small library of compounds are synthesized and evaluated for their in vitro antituber-
cular activity against Mycobacterium tuberculosis H37RV. Two compounds, -[(20,40-dinitrophenyl)
sulphonyl]-4-(p-aminophenylsulphonylamino)-6-(20-chlorophenyl)-pyrimidine-5-carboxamide Fb
and 2-hydrazino-4-(p-aminophenylsulphonylamino)-6-(20-chlorophenyl)-pyrimidine-5-carboxamide
Db were found to be the most active compounds in vitro with MIC of 0.02 lg/mL against MTB
and were more potent compared to isoniazid (MIC: 0.03 lg/mL).
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is a contagious and airborne disease caused
by Mycobacterium tuberculosis bacteria. It is a disease of pov-
erty and mostly TB deaths are in the developing world includ-
ing the majority of adults in their productive years [1].
Tuberculosis is often seen in those people who have weak
immune system and it is the major reason of fatality among
those infected with HIV [2]. The occurrence of both
multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), the indigence for more effective
chemotherapy for the treatment of TB [3]. The recent
chemotherapy DOTS (directly observed therapy short-
course) for TB and DOTS-Plus (DOTS plus Second-line TB
drugs) for MDR-TB given compliance treatment has up to
95% cure rate [4,5]. The fatality of the disease owing to the ori-
gin of multidrug-resistant TB poses a challenge to build a
novel agent to cure the drug resistant type of TB disease [6].
After many attempts in the design and synthesis of new thera-
peutic agent by pharmaceutical companies and academic insti-
tutions, the recent therapeutic agents are inadequate to cure
TB [7]. The currently recommended treatment for latent TB
infection is isoniazid given for six to nine months. The long
duration of this therapy and the potential toxicities of isoni-
azid means there is a major compliance problem associated
with the treatment regimen. Although new drugs are needed
to shorten the duration of treatment of latent TB infection,
the safety proﬁle for these drugs must be excellent, becausebercular
2 N.H. Bhuva et al.most patients with latent infection are destined never to expe-
rience activation of their TB [8]. Therefore, the need for newer,
more effective drugs that can achieve multiple goals in improv-
ing TB control is pressing. Recognizing these serious facts, we
initiated a programme to synthesize and screen diverse hetero-
cyclic entities like pyridines, phenothiazines and pyrimidines as
potential anti-tubercular agents. Based on our previous results
[9,10,11,14], we set upon a programme of making antitubercu-
lar agents, using the central dihydropyrimidine as the template
and adding versatile substituents on the various positions of
dihydropyrimidine ring and subjected them to antimycobacte-
rial screening.
Over the years, molecular hybridization based drug design
approach [12] has been exploited by many researchers in order
to develop some promising new hybrid chemical entities
(NHCEs), displaying signiﬁcant therapeutic values. The com-
bination of two pharmacophores into a single molecular skele-
ton is a well established approach for designing more potent
drugs with a signiﬁcant increase in activity. A hybrid molecule
acting on manifold targets is considered to be a better drug
candidate than drug combinations, since administration of sin-
gle drug will have more predictable pharmacokinetic and phar-
macodynamic properties with improved patient compliance
[13].
Owing to their well appreciated antitubercular and antimi-
crobial properties, we envisaged to design hybrid structures
having substituted pyrimidine and sulphonamide motifs con-
nected with a linker (Scheme 1). Therefore, in view of the
above facts and in continuation of our search on biologically
active hybrid molecules [9,14], herein we report the synthesis
of novel hybrid analogues (Aa–h to Fa–h) with their subsequent
antimycobacterial screening against Mycobacterium tubercu-
losis H37Rv (ATCC 27294) in BACTEC 12B medium using
the microplate alamar Blue assay (MABA). The above
facts reveal that it is a crucial situation to ﬁght against TB
hence to develop a new therapeutic agent which is more potent
than the existing drug and have a new mode of action (see
Schemes 2–4).
2. Experimental
2.1. Materials and methods
All research chemicals were purchased from Sigma–Aldrich
and used as such for the reactions. Reactions were monitored
by thin-layer chromatography (TLC) on pre-coated silica gel
GF254 plates from E-Merck Co and compounds visualized
either by exposure to UV. Melting points were determined in
open capillaries and are uncorrected. The IR spectra wereScheme
Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluat
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using the KBr pellet method. 1H and 13C NMR spectra were
recorded on a Bruker 300-MHz NMR spectrometer in
CDCl3 with TMS as internal standard. Mass spectrum was
recorded on a JOEL SX 102/DA-600-Mass spectrometer and
elemental analysis was carried out using a Heraus C,H,N rapid
analyser.
2.1.1. Preparation of 2-mercapto-4-amino-5-cyano-6-(aryl)-1,6-
dihydropyrimidine (1)
A mixture of substituted aromatic aldehyde (0.01 M),
malononitrile (0.01 M), thiourea (0.01 M) and con. HCl
(3 ml) in ethanol (30 ml) was heated under reﬂuxed condition
for 4 h. Then the reaction mixture was kept at room tempera-
ture for 2 h. The yellow crystalline product was obtained. The
product was isolated and recrystallized from ethanol.
Similarly, other compounds (1a–h) were synthesized.
2.1.2. Preparation of 2-mercapto-4-amino-6-(aryl)-pyrimidine-
5-carboxamide (2)
A mixture of (1) (0.01 M) was dissolved in conc. sulphuric acid
(20 ml) below 5 C and kept for 48 h. at room temperature.
The content was poured into ice cold water and ﬁltered. The
product was isolated and crystallized from ethanol. Similarly,
other compounds (2a–h) were synthesized.
2.1.3. Preparation of 2-mercapto-4-(p-acetamidophenylsulphony-
lamino)-6-(aryl)-pyrimidine-5-carboxamide (3)
A mixture of (2) (0.01 M) and p-acetamidophenylsulpho
nylchloride (0.01 M) in pyridine (15 ml) was heated under
reﬂuxed condition for 12 h. Then the reaction mixture was
poured into crushed ice. The product so obtained was recrys-
tallized from ethanol. Similarly, other compounds (3a–h) were
synthesized.
2.1.3.1. Preparation of 2-mercapto-4-(p-aminophenylsulphony-
lamino)-6-(aryl)-pyrimidine-5-carboxamide (Aa–h). A mixture
of (3) (0.01 M) and con. HCl (4 ml) in ethanol (25 ml) was
heated under reﬂuxed condition for 6 h. Then the reaction mix-
ture was poured into crushed ice. The product so obtained was
recrystallized from ethanol.
2.1.3.1.1. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
phenyl-pyrimidine-5-carboxamide (Aa). Yield (47%), mp 170–
172 C; 1H NMR (CDCl3) d= 2.79 (s, 1H, SH), 4.76 (s, 2H,
NH2), 6.43–6.45 (m, 2H, Ar-H), 7.06 (s, 2H, NH2), 7.39–7.42
(m, 3H, Ar-H), 7.42–7.43 (d, 2H, Ar-H, J= 4 Hz), 7.49–7.51
(m, 2H, Ar-H), 7.62 (s, 1H, NH); 13C NMR (d) 178.1, 170.9,
168.8, 167.8, 151.2, 132.8, 129.8, 129.2, 128.7 128.3, 127.1,
116.1, 109.3; Anal. Calcd: C, 50.86; H, 3.77; N, 17.44; O,1
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Scheme 2
Synthesis and biological evaluation of pyrimidinyl sulphonamide derivatives 311.96; Found: C, 50.81; H, 3.72; N, 17.39; O, 11.93; MS: m/z
401.
2.1.3.1.2. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(20-chlorophenyl)-pyrimidine-5-carboxamide (Ab). Yield
(49%), mp 167–169 C; 1H NMR (CDCl3) d= 2.77 (s, 1H,
SH), 4.78 (s, 2H, NH2), 6.41–6.44 (m, 2H, Ar-H), 7.08 (s,
2H, NH2), 7.18–7.21 (d, 2H, Ar-H, J= 12 Hz), 7.34–7.35 (d,
1H, Ar-H, J= 4 Hz), 7.40–7.41 (d, 1H, Ar-H, J= 4 Hz),
7.64 (s, 1H, NH) 7.66–7.67 (d, 2H, Ar-H, J= 4 Hz); 13C
NMR (d) 178.2, 168.8, 167.9, 167.2, 151.2, 132.5, 130.3,
130.0, 129.8, 129.4, 128.8, 128.1, 127.3, 116.8, 109.2; Anal.
Calcd: C, 46.84; H, 3.24; N, 16.07; O, 11.01; Found: C,
48.86; H, 3.26; N, 16.08, O, 10.97; MS: m/z 435.
2.1.3.1.3. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(40-chlorophenyl)-pyrimidine-5-carboxamide (Ac). YieldPlease cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluati
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2(51%), mp 145–147 C; 1H NMR (CDCl3) d= 2.78 (s, 1H,
SH), 4.78 (s, 2H, NH2), 6.45–6.48 (d, 2H, Ar-H, J= 12 Hz),
7.08 (s, 2H, NH2), 7.33–7.34 (d, 2H, Ar-H, J= 4 Hz), 7.42–
7.43 (d, 2H, Ar-H), 7.60 (s, 1H, NH), 7.66–7.67 (d, 2H, Ar-
H, J= 4 Hz); 13C NMR (d) 178.3, 168.7, 168.1, 167.6, 151.4,
134.5, 131.3, 129.8, 129.5, 128.8, 128.2, 116.7, 109.4; Anal.
Calcd: C, 46.84; H, 3.24; N, 16.07; O, 11.01; Found: C,
48.82; H, 3.28; N, 16.09, O, 10.96; MS: m/z 435.
2.1.3.1.4. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(30-bromophenyl)pyrimidine-5-carboxamide (Ad). Yield
(61%), mp 139–141 C; 1H NMR (CDCl3) d= 2.76 (s, 1H,
SH), 4.77 (s, 2H, NH2), 6.41–6.43 (m, 2H, Ar-H), 7.03 (s,
2H, NH2), 7.20–7.21 (d, 1H, Ar-H, J= 4 Hz), 7.38–7.41 (d,
2H, Ar-H, J= 12 Hz), 7.64 (s, 1H, NH), 7.66–7.69 (m, 3H,
Ar-H); 13C NMR (d) 178.5, 171.5, 168.5, 168.1, 151.5, 133.5,on of pyrimidinyl sulphonamide derivatives as promising class of antitubercular
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4 N.H. Bhuva et al.131.8, 131.2, 129.8, 129.6, 128.3, 126.2, 123.8, 116.5, 109.6;
Anal. Calcd: C, 42.51; H, 2.94; N, 14.58, O, 9.99; Found: C,
42.56; H, 2.96; N, 14.56, O, 9.96; MS: m/z 480.
2.1.3.1.5. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(40-methoxyphenyl)-pyrimidine-5-carboxamide (Ae). Yield
(48%), mp 140–142 C; 1H NMR (CDCl3) d= 2.79 (s, 1H,
SH), 3.77 (s, 3H, OCH3), 4.79 (s, 2H, NH2), 6.43–6.46 (m,
2H, Ar-H), 7.09 (s, 2H, NH2), 6.81–6.82 (d, 2H, Ar-H,
J= 4 Hz), 7.32–7.33 (d, 2H, Ar-H, J= 4 Hz), 7.64 (s, 1H,
NH), 7.74–7.75 (m, 2H, Ar-H); 13C NMR (d) 178.6, 171.7,
168.7, 168.2, 160.8, 151.8, 129.5, 128.4 127.8, 125.2, 116.7,
114.7, 109.8, 55.1; Anal. Calcd: C, 50.10; H, 3.97; N, 16.23,
O, 14.83; Found: C, 50.13; H, 3.98; N, 16.26, O, 14.81; MS:
m/z 431.
2.1.3.1.6. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(20-hydroxyphenyl)-pyrimidine-5-carboxamide (Af). Yield
(53%), mp 121–123 C; 1H NMR (CDCl3) d= 2.76 (s, 1H,
SH), 4.72 (s, 2H, NH2), 5.08 (s, 1H, OH), 6.41–6.43 (d, 2H,
Ar-H, J= 8 Hz), 7.04 (s, 2H, NH2), 6.82–6.83 (d, 2H, Ar-H,
J= 4 Hz), 6.79–6.80 (d, 1H, Ar-H, J= 4 Hz), 6.89–6.90 (d,
1H, Ar-H, J= 4 Hz), 7.04–7.06 (m, 1H, Ar-H), 7.66 (s, 1H,
NH); 13C NMR (d) 178.5, 171.4, 168.8, 168.3, 155.5, 151.7,
130.3, 129.8, 128.8, 128.2, 121.8, 120.4, 116.7, 109.8; Anal.
Calcd: C, 48.91; H, 3.62; N, 16.78, O, 15.33; Found: C,
48.86; H, 3.67; N, 16.74, O, 15.29; MS: m/z 417.
2.1.3.1.7. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(40-hydroxyphenyl)-pyrimidine-5-carboxamide (Ag). Yield
(60%), mp 151–153 C; 1H NMR (CDCl3) d= 2.78 (s, 1H,
SH), 4.78 (s, 2H, NH2), 5.11 (s, 1H, –OH), 6.41–6.42 (d, 2H,
Ar-H, J= 4 Hz), 7.04 (s, 2H, –NH2), 6.83–6.84 (d, 2H, Ar-
H, J= 4 Hz), 6.77–6.78 (d, 1H, Ar-H, J= 4 Hz), 6.89–6.91
(m, 2H, Ar-H), 7.09–7.10 (m, 2H, Ar-H), 7.63 (s, 1H, –NH);
13C NMR (d) 178.7, 171.5, 168.7, 168.1, 158.5, 151.7, 129.5,
128.6, 128.0, 125.8, 116.8, 116.1, 109.6; Anal. Calcd: C,
48.91; H, 3.62; N, 16.78, O, 15.33; Found: C, 48.86; H, 3.67;
N, 16.74, O, 15.29; MS: m/z 417.
2.1.3.1.8. 2-Mercapto-4-(p-aminophenylsulphonylamino)-6-
(40-nitrophenyl)-pyrimidine-5-carbocamide (Ah). Yield (51%),
mp 152–154 C; 1H NMR (CDCl3) d= 2.81 (s, 1H, SH),
4.78 (s, 2H, NH2), 6.43–6.44 (d, 2H, Ar-H, J= 4 Hz), 6.87–Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluat
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.26.88 (m, 2H, Ar-H) 7.03 (s, 2H, NH2), 7.64 (s, 1H, NH),
7.84–7.85 (m, 2H, Ar-H), 8.28–8.29 (m, 2H, Ar-H); 13C
NMR (d) 178.6, 171.6, 168.7, 168.0, 151.5, 148.7, 139.5,
129.6, 128.7, 127.9, 121.8, 116.4, 109.8; Anal. Calcd: C,
45.73; H, 3.16; N, 18.82, O, 17.92; Found: C, 45.78; H, 3.13;
N, 18.78, O, 17.94; MS: m/z 446.
2.1.4. Preparation of 2-methylthio-4-amino-6-(aryl)-
pyrimidine-5-carboxamide (4)
A mixture of (2) (0.01 M), dimethyl sulphate (0.01 M) in etha-
nol (30 ml) and 40% aq. NaOH (2.0 ml) was stirred for 12 h. at
room temperature. The content was poured into ice cold water
and ﬁltered. The product was isolated and crystallized from
ethanol.
Similarly, other compounds (4a–h) were synthesized.
2.1.5. Preparation of 2-methylthio-4-(p-
acetamidophenylsulphonylamino)-6-(aryl)-pyrimidine-5-
carboxamide (5)
A mixture of (4) (0.01 M) and p-acetamidophenylsulpho
nylchloride (0.01 M) in pyridine (15 ml) was heated under
reﬂuxed condition for 12 h. Then the reaction mixture was
poured into crushed ice. The product so obtained was recrys-
tallized from ethanol.
Similarly, other compounds (5a–h) were synthesized.
2.1.5.1. Preparation of 2-methylthio-4-(p-aminophenylsulpho-
nylamino)-6-(aryl)-pyrimidine-5-carboxamide (Ba–h). A mix-
ture of (5) (0.01 M) and con. HCl (4 ml) in ethanol (25 ml)
was heated under reﬂuxed condition for 6 h. Then the reaction
mixture was poured into crushed ice. The product so obtained
was recrystallized from methanol:dioxane (1:1).
2.1.5.1.1. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-aryl-pyrimidine-5-carbocamide (Ba). Yield (48%), mp 73–
75 C; 1H NMR (CDCl3) d= 2.40 (s, 3H, SCH3), 4.75 (s,
2H, NH2), 6.43–6.44 (m, 2H, Ar-H), 7.05 (s, 2H, NH2),
7.38–7.41 (m, 3H, Ar-H), 7.41–7.42 (d, 2H, Ar-H, J= 4 Hz),
7.49–7.50 (m, 2H, Ar-H), 7.63 (s, 1H, NH); 13C NMR (d)
171.6, 169.9, 168.2, 167.8, 151.4, 132.9, 129.6, 129.1, 128.9
128.3, 127.3, 116.3, 106.7, 14.2; Anal. Calcd C18H17N5O3S2:ion of pyrimidinyl sulphonamide derivatives as promising class of antitubercular
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N, 16.89; O, 11.53; MS: m/z 415.
2.1.5.1.2. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(20-chlorophenyl)-pyrimidine-5-carboxamide (Bb). Yield
(48%), mp 136–138 C; 1H NMR (CDCl3) d= 2.39 (s, 3H,
SCH3), 4.76 (s, 2H, NH2), 6.42–6.44 (m, 2H, Ar-H), 7.07 (s,
2H, NH2), 7.18–7.21 (d, 2H, Ar-H, J= 12 Hz), 7.33–7.34 (d,
1H, Ar-H, J= 4 Hz), 7.41–7.42 (d, 1H, Ar-H, J= 4 Hz),
7.63 (s, 1H, NH) 7.65–7.66 (d, 2H, Ar-H, J= 4 Hz); 13C
NMR (d) 171.4, 169.8, 167.9, 167.5, 151.3, 132.4, 130.1,
129.9, 129.7, 129.3, 128.7, 128.0, 127.4, 116.7, 106.2, 14.4;
Anal. Calcd: C18H16ClN5O3S2: C, 48.05; H, 3.58; N, 15.57;
O, 10.67; Found: C, 48.06; H, 3.56; N, 15.54, O, 10.63; MS:
m/z 449.
2.1.5.1.3. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(40-chlorophenyl)-pyrimidine-5-carboxamide (Bc). Yield
(53%), mp 159–161 C; 1H NMR (CDCl3) d= 2.38 (s, 3H,
SCH3), 4.79 (s, 2H, NH2), 6.45–6.47 (d, 2H, Ar-H), 7.09 (s,
2H, NH2), 7.33–7.34 (d, 2H, Ar-H, J= 4 Hz), 7.40–7.41 (d,
2H, Ar-H, J= 4 Hz), 7.59 (s, 1H, NH), 7.67–7.68 (d, 2H,
Ar-H, J= 4 Hz); 13C NMR (d) 171.5, 169.5, 168.3, 167.4,
151.5, 134.6, 131.4, 129.9, 129.4, 128.7, 128.2, 116.3, 106.7,
14.6; Anal. Calcd: C18H16ClN5O3S2: C, 48.05; H, 3.58; N,
15.57; O, 10.67; Found: C, 48.04; H, 3.59; N, 15.52, O,
10.61; MS: m/z 449.
2.1.5.1.4. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(30-bromophenyl)-pyrimidine-5-carboxamide (Bd). Yield
(59%), mp 124–125 C; 1H NMR (CDCl3) d= 2.37 (s, 1H,
SCH3), 4.75 (s, 2H, NH2), 6.42–6.44 (m, 2H, Ar-H), 7.06 (s,
2H, NH2), 7.22–7.23 (d, 1H, Ar-H, J= 4 Hz), 7.39–7.41 (d,
2H, Ar-H, J= 8 Hz), 7.65 (s, 1H, NH), 7.66–7.68 (m, 3H,
Ar-H); 13C NMR (d) 171.4, 170.0, 168.4, 167.8, 151.7, 133.4,
131.7, 131.2, 129.9, 128.3, 128.3, 126.4, 123.7, 116.4, 106.6,
14.3; Anal. Calcd: C18H16BrN5O3S2: C, 43.73; H, 3.26; N,
14.17; O, 9.71; Found: C, 43.70; H, 3.21; N, 14.19; O, 9.76;
MS: m/z 494.
2.1.5.1.5. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(40-methoxyphenyl)-pyrimidine-5-carboxamide (Be). Yield
(56%), mp 185–187 C; 1H NMR (CDCl3) d= 2.79 (s, 3H,
SCH3), 3.76 (s, 3H, OCH3), 4.76 (s, 2H, NH2), 6.43–6.45 (m,
2H, Ar-H), 7.08 (s, 2H, NH2), 6.83–6.84 (d, 2H, Ar-H,
J= 4 Hz), 7.33–7.34 (d, 2H, Ar-H, J= 4 Hz), 7.65 (s, 1H,
NH), 7.75–7.76 (m, 2H, Ar-H); 13C NMR (d) 171.4, 171.7,
169.6, 168.2, 167.5, 160.9, 151.7, 129.6, 128.6, 127.9, 125.3,
116.8, 114.6, 109.7, 55.3, 14.6; Anal. Calcd: C19H19N5O4S2:
C, 51.22; H, 4.30; N, 15.72; O, 14.72; Found: 51.18; H, 4.36;
N, 15.69; O, 14.74; MS: m/z 445.
2.1.5.1.6. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(20-hydroxyphenyl)-pyrimidine-5-carboxamide (Bf). Yield
(46%), mp 130–132 C; 1H NMR (CDCl3) d= 2.73 (s, 3H,
SCH3), 4.72 (s, 2H, NH2), 5.09 (s, 1H, OH), 6.41–6.42 (d,
2H, Ar-H, J= 4 Hz), 7.06 (s, 2H, NH2), 6.83–6.84 (d, 2H,
Ar-H, J= 4 Hz), 6.78–6.79 (d, 1H, Ar-H, J= 4 Hz), 6.88–
6.89 (d, 1H, Ar-H, J= 4 Hz), 7.05–7.06 (m, 1H, Ar-H), 7.64
(s, 1H, NH); 13C NMR (d) 171.3, 169.9, 168.4, 167.3, 155.6,
151.6, 130.5, 129.9, 128.7, 128.0, 121.6, 120.3, 116.8, 106.8,
14.5; Anal. Calcd: C19H17N5O4S2: C, 50.10; H, 3.97; N,
16.23; O, 14.83; Found: 50.16; H, 3.92; N, 14.89; O, 14.79;
MS: m/z 431.
2.1.5.1.7. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(40-hydroxyphenyl)-pyrimidine-5-carboxamide (Bg). Yield
(51%), mp 151–153 C; 1H NMR (CDCl3) d= 2.79 (s, 3H,Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluati
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2SCH3), 4.76 (s, 2H, NH2), 5.13 (s, 1H, OH), 6.42–6.43 (d,
2H, Ar-H, J= 4 Hz), 7.06 (s, 2H, NH2), 6.83–6.84 (d, 2H,
Ar-H, J= 4 Hz), 6.76–6.77 (d, 1H, Ar-H, J= 4 Hz), 6.89–
6.90 (m, 2H, Ar-H), 7.08–7.09 (m, 2H, Ar-H), 7.66 (s, 1H,
NH); 13C NMR (d) 171.5, 169.5, 168.3, 167.8, 158.8, 151.5,
129.3, 128.7, 128.3, 125.5, 116.8, 116.3, 106.6, 14.6; Anal.
Calcd: C19H17N5O4S2: C, 50.10; H, 3.97; N, 16.23; O, 14.83;
Found: 50.15; H, 3.93; N, 14.86; O, 14.72; MS: m/z 431.
2.1.5.1.8. 2-Methylthio-4-(p-aminophenylsulphonylamino)-
6-(40-nitrophenyl)-pyrimidine-5-carboxamide (Bh). Yield
(52%), mp 117–119 C; 1H NMR (CDCl3) d= 2.81 (s, 3H,
SCH3), 4.76 (s, 2H, NH2), 6.42–6.43 (d, 2H, Ar-H), 6.88–
6.89 (m, 2H, Ar-H) 7.06 (s, 2H, NH2), 7.67 (s, 1H, NH),
7.83–7.84 (m, 2H, Ar-H), 8.26–8.27 (m, 2H, Ar-H); 13C
NMR (d) 171.6, 169.9, 168.3, 167.9, 151.4, 148.6, 139.4,
129.5, 128.3, 127.8, 121.7, 116.5, 106.6, 14.3; Anal. Calcd:
C18H16N6O5S2: C, 46.85; H, 3.50; N, 18.25; O, 17.37; Found:
C, 46.81; H, 3.46; N, 18.29; O, 17.41; MS: m/z 460.
2.1.6. Preparation of 2-methylsulphonyl-4-amino-6-(aryl)-
pyrimidine-5-carboxamide (6)
A mixture of 2-methylthio-4-amino-6-(aryl)-pyrimidine-5-car
boxamide (0.01 M) was dissolved in 20 ml of gla. acetic acid
and added 12 ml of hydrogen peroxide and then kept for
48 h. at room temperature. The content was poured into ice
cold water and ﬁltered. The product was isolated and crystal-
lized from ethanol.
2.1.7. Preparation of 2-methysulphonyl-4-(p-
acetamidophenylsulphonylamino)-6-(aryl)-pyrimidine-5-
carboxamide (7)
A mixture of (6) (0.01 M) and p-acetamidophenylsulpho
nylchloride (0.01 M) in pyridine (15 ml) was heated under
reﬂuxed condition for 12 h. Then the reaction mixture was
poured into crushed ice. The product so obtained was recrys-
tallized from ethanol.
Similarly, other compounds (7a–h) were synthesized.
2.1.7.1. Preparation of 2-methysulphonyl-4-(p-aminophenyl-
sulphonylamino)-6-(aryl)-pyrimidine-5-carboxamide (Ca–h). A
mixture of (7) (0.01 M) and con. HCl (4 ml) in ethanol
(25 ml) was heated under reﬂuxed condition for 6 h. Then
the reaction mixture was poured into crushed ice. The product
so obtained was recrystallized from methanol:dioxane (1:1).
2.1.7.1.1. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-aryl-pyrimidine-5-carboxamide (Ca). Yield (46%),
mp 94–96 C; 1H NMR (CDCl3) d= 3.06 (s, 3H, CH3), 4.74
(s, 2H, NH2), 6.42–6.43 (m, 2H, Ar-H), 7.06 (s, 2H, NH2),
7.39–7.41 (m, 3H, Ar-H), 7.42–7.43 (d, 2H, Ar-H, J= 4 Hz),
7.48–7.49 (m, 2H, Ar-H), 7.62 (s, 1H, NH); 13C NMR (d)
172.8, 168.9, 168.2, 164.6, 151.3, 132.8, 129.7, 129.3, 128.7
128.4, 127.5, 116.3, 116.0, 44.2; Anal. Calcd C18H17N5O5S2:
C, 48.31; H, 3.83; N, 15.65; O, 17.88; Found: C, 48.36; H,
3.85; N, 15.60; O, 17.82; MS: m/z 447.
2.1.7.1.2. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(20-chlorophenyl)-pyrimidine-5-carboxamide (Cb).
Yield (65%), mp 110–112 C; 1H NMR (CDCl3) d= 3.09 (s,
3H, CH3), 4.73 (s, 2H, NH2), 6.41–6.42 (m, 2H, Ar-H), 7.05
(s, 2H, NH2), 7.19–7.21 (d, 2H, Ar-H, J= 8 Hz), 7.34–7.35
(d, 1H, Ar-H, J= 4 Hz), 7.40–7.41 (d, 1H, Ar-H, J= 4 Hz),
7.65 (s, 1H, NH) 7.62–7.63 (d, 2H, Ar-H, J= 4 Hz); 13Con of pyrimidinyl sulphonamide derivatives as promising class of antitubercular
015.05.007
6 N.H. Bhuva et al.NMR (d) 172.4, 168.9, 167.9, 164.5, 151.2, 132.5, 130.2, 129.8,
129.5, 129.4, 128.6, 128.1, 127.3, 116.7, 116.2, 44.4; Anal.
Calcd: C18H16ClN5O5S2: C, 44.86; H, 3.35; N, 14.53; O,
16.60; Found: C, 44.81; H, 3.38; N, 14.56; O, 16.64; MS: m/z
481.
2.1.7.1.3. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(40-chlorophenyl)-pyrimidine-5-carboxamide (Cc).
Yield (58%), mp 87–89 C; 1H NMR (CDCl3) d= 3.08 (s,
3H, CH3), 4.76 (s, 2H, NH2), 6.45–6.46 (d, 2H, Ar-H,
J= 4 Hz), 7.06 (s, 2H, NH2), 7.32–7.33 (d, 2H, Ar-H,
J= 4 Hz), 7.39–7.40 (d, 2H, Ar-H, J= 4 Hz), 7.56 (s, 1H,
NH), 7.65–7.66 (d, 2H, Ar-H, J= 4 Hz); 13C NMR (d)
172.5, 168.5, 168.3, 164.4, 151.6, 134.7, 131.3, 129.8, 129.3,
128.8, 128.1, 116.7, 116.3, 44.6; Anal. Calcd:
C18H16ClN5O5S2: C, 44.85; H, 3.38; N, 14.55; O, 16.58;
Found: C, 44.81; H, 3.38; N, 14.56; O, 16.64; MS: m/z 481.
2.1.7.1.4. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(30-bromophenyl)-pyrimidine-5-carboxamide (Cd).
Yield (55%), mp 116–118 C; 1H NMR (CDCl3) d= 3.07 (s,
3H, CH3), 4.78 (s, 2H, NH2), 6.43–6.45 (m, 2H, Ar-H), 7.09
(s, 2H, NH2), 7.24–7.25 (d, 1H, Ar-H, J= 4 Hz), 7.36–7.38
(d, 2H, Ar-H, J= 8 Hz), 7.66 (s, 1H, NH), 7.63–7.64 (m,
3H, Ar-H); 13C NMR (d) 172.4, 168.8, 168.2, 164.7, 151.6,
133.3, 131.8, 131.3, 130.1, 128.4, 128.1, 126.5, 123.8, 116.6,
116.3, 44.3; Anal. Calcd: C18H16BrN5O5S2: C, 41.07; H,
3.06; N, 13.30; O, 15.20; Found: C, 41.02; H, 3.03; N, 13.35;
O, 15.24; MS: m/z 526.
2.1.7.1.5. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(40-methoxyphenyl)-pyrimidine-5-carboxamide
(Ce). Yield (59%), mp 108–110 C; 1H NMR (CDCl3)
d= 3.10 (s, 3H, CH3), 3.78 (s, 3H, OCH3), 4.77 (s, 2H,
NH2), 6.44–6.46 (m, 2H, Ar-H), 7.04 (s, 2H, NH2), 6.81–6.82
(d, 2H, Ar-H, J= 4 Hz), 7.32–7.33 (d, 2H, Ar-H, J= 4 Hz),
7.68 (s, 1H, NH), 7.77–7.78 (m, 2H, Ar-H); 13C NMR (d)
172.3, 168.7, 168.0, 164.8, 160.8, 151.5, 129.8, 128.3, 127.8,
125.5, 116.9, 116.6, 116.0, 55.4, 44.6; Anal. Calcd:
C19H19N5O6S2: C, 47.79; H, 4.01; N, 14.67; O, 20.10; Found:
C, 47.74; H, 4.05; N, 14.61; O, 20.14; MS: m/z 477.
2.1.7.1.6. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(20-hydroxyphenyl)-pyrimidine-5-carboxamide (Cf).
Yield (60%), mp 127–129 C; 1H NMR (CDCl3) d= 3.13 (s,
3H, CH3), 4.74 (s, 2H, NH2), 5.11 (s, 1H, OH), 6.43–6.44 (d,
2H, Ar-H, J= 4 Hz), 7.08 (s, 2H, NH2), 6.85–6.86 (d, 2H,
Ar-H, J= 4 Hz), 6.76–6.77 (d, 1H, Ar-H, J= 4 Hz), 6.85–
6.86 (d, 1H, Ar-H, J= 4 Hz), 7.04–7.05 (m, 1H, Ar-H), 7.66
(s, 1H, NH); 13C NMR (d) 172.3, 168.9, 168.3, 164.5, 155.7,
151.5, 130.3, 129.8, 128.4, 128.0, 121.3, 120.5, 116.8, 116.5,
44.5; Anal. Calcd: C19H17N5O6S2: C, 46.64; H, 3.70; N,
15.11; O, 20.71; Found: C, 46.67; H, 3.73; N, 15.16; O,
20.74; MS: m/z 463.
2.1.7.1.7. 2-Methylsulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(40-hydroxyphenyl)-pyrimidine-5-carboxamide (Cg).
Yield (47%), mp 167–169 C; 1H NMR (CDCl3) d= 3.14
(s, 3H, CH3), 4.73 (s, 2H, NH2), 5.11 (s, 1H, OH), 6.42–
6.43 (d, 2H, Ar-H), 7.08 (s, 2H, NH2), 6.84–6.85 (d, 2H,
Ar-H, J= 4 Hz), 6.74–6.75 (d, 1H, Ar-H, J= 4 Hz), 6.86–
6.87 (m, 2H, Ar-H), 7.06–7.07 (m, 2H, Ar-H), 7.68 (s, 1H,
NH); 13C NMR (d) 172.5, 168.5, 168.0, 164.6, 158.9, 151.3,
129.2, 128.5, 128.1, 125.3, 116.8, 116.4, 116.0, 44.6; Anal.
Calcd: C19H17N5O4S2: C, 50.10; H, 3.97; N, 16.23; O,
14.83; Anal. Calcd: C19H17N5O6S2: C, 46.64; H, 3.70; N,Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluat
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.215.11; O, 20.71; Found: C, 46.68; H, 3.71; N, 15.18; O,
20.77; MS: m/z 463.
2.1.7.1.8. 2-Methysulphonyl-4-(p-aminophenylsulphony-
lamino)-6-(40-nitrophenyl)-pyrimidine (Ch). Yield (51%), mp
133–135 C; 1H NMR (CDCl3) d= 3.07 (s, 3H, CH3), 4.78
(s, 2H, NH2), 6.44–6.45 (d, 2H, Ar-H, J= 4 Hz), 6.87–6.88
(m, 2H, Ar-H) 7.08 (s, 2H, NH2), 7.68 (s, 1H, NH), 7.84–
7.85 (m, 2H, Ar-H), 8.24–8.26 (m, 2H, Ar-H); 13C NMR (d)
172.6, 169.5, 168.0, 164.9, 151.5, 148.7, 139.3, 129.6, 128.2,
127.9, 121.5, 116.6, 116.2, 44.3; Anal. Calcd: C18H16N6O7S2:
C, 43.90; H, 3.27; N, 17.06; O, 22.74; Found: C, 43.96; H,
3.21; N, 17.02; O, 22.70; MS: m/z 492.
2.1.7.2. Preparation of 2-hydrazino-4-(p-aminophenylsulphony-
lamino)-6-(aryl)-pyrimidine-5-carboxamide (Da–h). A mixture
of (Ba–h) (0.01 M) and hydrazine hydrate (0.02 M) in ethanol
(30 ml) was heated under reﬂux condition for ﬁve hours. The
content was poured into ice cold water and ﬁltered. The pro-
duct was isolated and crystallized from methanol:dioxane
(1:3).
2.1.7.2.1. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
arylpyrimidine-5-carboxamide (Da). Yield (68%), mp 141–
143 C; 1H NMR (CDCl3) d= 3.58 (s, 2H, NH2), 4.39 (s,
1H, NH), 4.73 (s, 2H, NH2), 6.43–6.44 (m, 2H, Ar-H), 7.08
(s, 2H, NH2), 7.38–7.40 (m, 3H, Ar-H), 7.41–7.42 (d, 2H,
Ar-H), 7.46–7.47 (m, 2H, Ar-H), 7.63 (s, 1H, NH); 13C
NMR (d) 169.8, 169.1, 168.2, 159.6, 151.4, 132.7, 129.8,
129.3, 128.6 128.3, 127.6, 116.3, 106.0; Anal. Calcd
C17H17N7O3S: C, 51.12; H, 4.29; N, 24.55; O, 12.02; Found:
C, 51.08; H, 4.23; N, 24.59; O, 12.04; MS: m/z 399.
2.1.7.2.2. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(20-chlorophenyl)-pyrimidine-5-carboxamide (Db). Yield
(47%), mp 128–130 C; 1H NMR (CDCl3) d= 3.59 (s, 2H,
NH2), 4.37 (s, 1H, NH), 4.72 (s, 2H, NH2), 6.42–6.43 (m,
2H, Ar-H), 7.06 (s, 2H, NH2), 7.18–7.19 (d, 2H, Ar-H,
J= 4 Hz), 7.36–7.37 (d, 1H, Ar-H, J= 4 Hz), 7.42–7.43 (d,
1H, Ar-H, J= 4 Hz), 7.68 (s, 1H, NH) 7.61–7.62 (d, 2H,
Ar-H); 13C NMR (d) 169.7, 168.9, 167.9, 159.5, 151.3, 132.6,
130.1, 129.7, 129.3, 129.2, 128.7, 128.1, 127.5, 116.8, 105.8;
Anal. Calcd: C17H16ClN7O3S: C, 47.06; H, 3.72; N, 22.60; O,
11.06; Found: C, 47.01; H, 3.76; N, 22.56; O, 11.02; MS: m/z 433.
2.1.7.2.3. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(40-chlorophenyl)-pyrimidine-5-carboxamide (Dc). Yield
(63%), mp 149–151 C; 1H NMR (CDCl3) d= 3.56 (s, 2H,
NH2), 4.38 (s, 1H, NH), 4.75 (s, 2H, NH2), 6.46–6.47 (d, 2H,
Ar-H, J= 4 Hz), 7.09 (s, 2H, NH2), 7.34–7.35 (d, 2H, Ar-H,
J= 4 Hz), 7.37–7.38 (d, 2H, Ar-H, J= 4 Hz), 7.58 (s, 1H,
NH), 7.63–7.64 (d, 2H, Ar-H, J= 4 Hz); 13C NMR (d)
169.8, 168.8, 168.2, 159.1, 151.7, 134.6, 131.5, 129.9, 129.4,
128.7, 128.0, 116.7, 105.8; Anal. Calcd: C17H16ClN7O3S: C,
47.06; H, 3.72; N, 22.60; O, 11.06; Found: C, 47.03; H, 3.72;
N, 22.54; O, 11.05; MS: m/z 433.
2.1.7.2.4. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(30-bromophenyl)-pyrimidine-5-carboxamide (Dd). Yield
(66%), mp 181–183 C; 1H NMR (CDCl3) d= 3.57 (s, 2H,
NH2), 4.40 (s, 1H, NH), 4.76 (s, 2H, NH2), 6.44–6.45 (m,
2H, Ar-H), 7.06 (s, 2H, NH2), 7.23–7.24 (d, 1H, Ar-H),
7.38–7.39 (d, 2H, Ar-H, J= 4 Hz), 7.68 (s, 1H, NH), 7.61–
7.62 (m, 3H, Ar-H); 13C NMR (d) 169.7, 168.8, 168.3, 159.7,
151.7, 133.4, 131.7, 131.5, 130.1, 128.5, 128.1, 126.6, 123.7,
116.6, 105.7; Anal. Calcd: C17H16BrN7O3S: C, 42.69; H,ion of pyrimidinyl sulphonamide derivatives as promising class of antitubercular
015.05.007
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10.08; MS: m/z 477.
2.1.7.2.5. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(40-methoxyphenyl)-pyrimidine-5-carboxamide (De). Yield
(54%), mp 119–121 C; 1H NMR (CDCl3) d= 3.59 (s, 2H,
NH2), 3.79 (s, 3H, OCH3), 4.39 (s, 1H, NH), 4.78 (s, 2H,
NH2), 6.46–6.48 (m, 2H, Ar-H), 7.06 (s, 2H, NH2), 6.83–6.84
(d, 2H, Ar-H, J= 4 Hz), 7.31–7.32 (d, 2H, Ar-H, J= 4 Hz),
7.69 (s, 1H, NH), 7.76–7.77 (m, 2H, Ar-H); 13C NMR (d)
169.8, 168.9, 168.3, 164.8, 158.8, 151.6, 129.7, 128.4, 127.9,
125.3, 116.9, 116.5, 105.7, 55.6; Anal. Calcd: C18H19N7O4S:
C, 50.34; H, 4.46; N, 22.83; O, 14.90; Found: C, 50.38; H,
4.41; N, 22.86; O, 14.86; MS: m/z 429.
2.1.7.2.6. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(20-hydroxyphenyl)-pyrimidine-5-carboxamide (Df). Yield
(46%), mp 134–135 C; 1H NMR (CDCl3) d= 3.56 (s, 2H,
NH2), 4.36 (s, 1H, NH), 4.76 (s, 2H, NH2), 5.13 (s, 1H,
OH), 6.45–6.46 (d, 2H, Ar-H, J= 4 Hz), 7.07 (s, 2H, NH2),
6.83–6.84 (d, 2H, Ar-H, J= 4 Hz), 6.75–6.76 (d, 1H, Ar-H,
J= 4 Hz), 6.87–6.88 (d, 1H, Ar-H, J= 4 Hz), 7.06–7.07 (m,
1H, Ar-H), 7.68 (s, 1H, NH); 13C NMR (d) 169.7, 168.8,
168.3, 159.8, 155.6, 151.3, 130.5, 129.7, 128.5, 128.0, 121.5,
120.7, 116.8, 105.5; Anal. Calcd: C17H17N7O4S: C, 49.15; H,
4.12; N, 23.60; O, 15.41; Found: C, 49.11; H, 4.08; N, 23.64;
O, 15.45; MS: m/z 415.
2.1.7.2.7. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(40-hydroxyphenyl)-pyrimidine-5-carboxamide (Dg). Yield
(50%), mp 153–155 C; 1H NMR (CDCl3) d= 3.59 (s, 2H,
NH2), 4.38 (s, 1H, NH), 4.76 (s, 2H, NH2), 5.08 (s, 1H,
OH), 6.43–6.44 (d, 2H, Ar-H), 7.09 (s, 2H, NH2), 6.83–6.84
(d, 2H, Ar-H, J= 4 Hz), 6.76–6.77 (d, 1H, Ar-H, J= 4 Hz),
6.85–6.86 (m, 2H, Ar-H), 7.04–7.05 (m, 2H, Ar-H), 7.65 (s,
1H, NH); 13C NMR (d) 169.6, 168.8, 168.3, 164.6, 159.6,
151.5, 129.3, 128.7, 128.1, 125.5, 116.7, 116.5, 105.9; Anal.
Calcd: C17H17N7O4S: C, 49.15; H, 4.12; N, 23.60; O, 15.41;
Found: C, 49.11; H, 4.08; N, 23.64; O, 15.45; MS: m/z 415.
2.1.7.2.8. 2-Hydrazino-4-(p-aminophenylsulphonylamino)-6-
(40-nitrophenyl)-pyrimidine-5-carboxamide (Dh). Yield (72%),
mp 128–130 C; 1H NMR (CDCl3) d= 3.61 (s, 2H, NH2),
4.40 (s, 1H, NH), 4.76 (s, 2H, NH2), 6.45–6.46 (d, 2H, Ar-H,
J= 4 Hz), 6.88–6.89 (m, 2H, Ar-H), 7.07 (s, 2H, NH2), 7.67
(s, 1H, NH), 7.83–7.84 (m, 2H, Ar-H), 8.25–8.26 (m, 2H,
Ar-H); 13C NMR (d) 169.8, 169.1, 168.2, 159.6, 151.7, 148.8,
139.5, 129.3, 128.3, 127.7, 121.4, 116.5, 105.7; Anal. Calcd:
C17H16N8O5S: C, 45.94; H, 3.63; N, 25.21; O, 18.00; Found:
C, 45.98; H, 3.60; N, 25.24; O, 18.07; MS: m/z 444.
2.1.8. Preparation of 2-[(20,40-dinitrophenyl)thio]-4-amino-6-
(aryl)-pyrimidine-5-carboxamide (8)
A mixture of (1) (0.01 M) and 1-chloro-2,4-dinitrobanzene
(0.01 M) in ethanol (30 ml) and 2 ml of 10% aq. NaOH solu-
tion was heated under reﬂuxed condition for three hrs. The
content was poured into ice cold water and ﬁltered. The pro-
duct was isolated and crystallized from ethanol. Similarly,
other compounds (8a–h) were synthesized.
2.1.9. Preparation of 2-[(20,40-dinitrophenyl)thio]-4-(p-
acetamidophenylsulphonylamino)-6-(aryl)-pyrimidine-5-
carboxamide (9)
A mixture of (8) (0.01 M) and p-acetamidophenylsulpho
nylchloride (0.01 M) in pyridine (15 ml) was heated underPlease cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluati
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2reﬂuxed condition for 12 h. Then the reaction mixture was
poured into crushed ice. The product so obtained was recrystal-
lized from ethanol. Similarly, other compounds (8a–h) were
synthesized.2.1.9.1. Preparation of 2-[(20,40-dinitrophenyl)thio]-4-(p-
aminophenylsulphonylamino)-6-(aryl)-pyrimidine-5-carboxam-
ide (Ea–h). A mixture of (9) (0.01 M) and con. HCl (4 ml) in
ethanol (25 ml) was heated under reﬂuxed condition for 6 h.
Then the reaction mixture was poured into crushed ice. The
product so obtained was recrystallized from ethanol:dioxane
(1:4).
2.1.9.1.1. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-arylpyrimidine-5-carboxamide (Ea). Yield
(58%), mp 94–96 C; 1H NMR (CDCl3) d= 4.74 (s, 2H,
NH2), 6.44–6.45 (m, 2H, Ar-H), 7.07 (s, 2H, NH2), 7.20–7.21
(d, 1H, Ar-H, J= 4 Hz), 7.39–7.40 (m, 3H, Ar-H), 7.42–7.43
(d, 2H, Ar-H, J= 4 Hz), 7.48–7.49 (m, 2H, Ar-H), 7.65 (s,
1H, NH), 8.40–8.41 (d, 1H, Ar-H, J= 4 Hz), 8.94 (s, 1H,
Ar-H); 13C NMR (d) 171.4, 169.6, 168.9, 168.0, 151.4, 150.0,
146.3, 133.9, 133.0, 131.4, 129.9, 129.2, 128.9, 128.2, 127.8,
119.3, 116.8, 109.7; Anal. Calcd C23H17N7O7S2: C, 48.67; H,
3.02; N, 17.28; O, 19.73; Found: C, 48.62; H, 3.06; N, 17.23;
O, 19.76; MS: m/z 567.
2.1.9.1.2. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(20-chlorophenyl)-pyrimidine-5-carboxam-
ide (Eb). Yield (45%), mp 122–124 C; 1H NMR (CDCl3)
d= 4.72 (s, 2H, NH2), 6.42–6.43 (m, 2H, Ar-H), 7.06 (s,
2H, NH2), 7.18–7.19 (d, 2H, Ar-H, J= 4 Hz), 7.21–7.22
(d, 1H, Ar-H, J= 4 Hz) 7.36–7.37 (d, 1H, Ar-H,
J= 4 Hz), 7.42–7.43 (d, 1H, Ar-H, J= 4 Hz), 7.68 (s, 1H,
NH), 7.61–7.62 (d, 2H, Ar-H, J= 4 Hz), 8.39–8.40 (d, 1H,
Ar-H, J= 4 Hz), 8.96 (s, 1H, Ar-H); 13C NMR (d) 171.3,
169.5, 168.7, 168.1, 151.3, 150.1, 146.2, 133.9, 132.1, 131.4,
129.9, 129.1, 128.8, 127.9, 127.3, 119.2, 116.9, 109.8; Anal.
Calcd: C23H16ClN7O7S2: C, 45.89; H, 2.89; N, 16.29; O,
18.60; Found: C, 45.82; H, 2.93; N, 16.34; O, 18.56; MS:
m/z 601.
2.1.9.1.3. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(40-chlorophenyl)-pyrimidine-5-carboxam-
ide (Ec). Yield (49%), mp 160–162 C; 1H NMR (CDCl3)
d= 4.75 (s, 2H, NH2), 6.46–6.47 (d, 2H, Ar-H), 7.09 (s, 2H,
NH2), 7.22–7.23 (d, 1H, Ar-H, J= 4 Hz), 7.34–7.35 (d, 2H,
Ar-H, J= 4 Hz), 7.37–7.38 (d, 2H, Ar-H, J= 4 Hz), 7.58 (s,
1H, NH), 7.63–7.64 (d, 2H, Ar-H, J= 4 Hz), 8.37–8.38 (d,
1H, Ar-H, J= 4 Hz), 8.92 (s, 1H, Ar-H); 13C NMR (d)
171.3, 169.5, 168.8, 167.9, 151.6, 149.9, 146.4, 133.8, 131.4,
129.8, 129.1, 128.7, 128.0, 127.6, 119.1, 116.9, 109.6; Anal.
Calcd: C23H16ClN7O7S2: C, 45.89; H, 2.89; N, 16.29; O,
18.60; Found: C, 45.82; H, 2.93; N, 16.34; O, 18.56; MS: m/z
601.
2.1.9.1.4. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(30-bromophenyl)-pyrimidine-5-carboxam-
ide (Ed). Yield (61%), mp 160–162 C; 1H NMR (CDCl3)
d= 4.78 (s, 2H, NH2), 6.43–6.44 (m, 2H, Ar-H), 7.09 (s, 2H,
NH2), 7.21–7.22 (d, 2H, Ar-H, J= 4 Hz), 7.39–7.40 (d, 2H,
Ar-H, J= 4 Hz), 7.60–7.61 (m, 3H, Ar-H), 7.69 (s, 1H,
NH), 8.38–8.39 (d, 1H, Ar-H, J= 4 Hz), 8.91 (s, 1H, Ar-H);
13C NMR (d) 171.4, 169.6, 168.7, 168.0, 151.7, 149.8, 146.3,
135.6, 131.5, 133.0, 131.9, 131.5, 130.9, 129.6, 128.4, 127.7,
126.8, 123.3, 119.3, 116.8, 109.7; Anal. Calcd:on of pyrimidinyl sulphonamide derivatives as promising class of antitubercular
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8 N.H. Bhuva et al.C23H16BrN7O7S2: C, 42.73; H, 2.49; N, 15.17; O, 17.32;
Found: C, 42.78; H, 2.44; N, 15.19; O, 17.37; MS: m/z 646.
2.1.9.1.5. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(40-methoxyphenyl)-pyrimidine-5-carbox-
amide (Ee). Yield (52%), mp 136–138 C; 1H NMR (CDCl3)
d= 3.77 (s, 3H, OCH3), 4.76 (s, 2H, NH2), 6.47–6.48 (m,
2H, Ar-H), 6.84–6.85 (d, 2H, Ar-H, J= 4 Hz), 7.09 (s, 2H,
NH2), 7.22–7.23 (d, 1H, Ar-H), 7.32–7.33 (d, 2H, Ar-H,
J= 4 Hz), 7.71 (s, 1H, NH), 7.77–7.78 (m, 2H, Ar-H), 8.37–
8.38 (d, 1H, Ar-H), 8.89 (s, 1H, Ar-H). Anal. Calcd:
C24H19N7O8S2: C, 48.24; H, 3.20; N, 16.41; O, 21.42; Found:
C, 48.28; H, 3.16; N, 16.38; O, 21.45; MS: m/z.
2.1.9.1.6. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(20-hydroxyphenyl)-pyrimidine-5-carbox-
amide (Ef). Yield (63%), mp 154–156 C; 1H NMR (CDCl3)
d= 4.77 (s, 2H, NH2), 5.16 (s, 1H, OH), 6.46–6.47 (d, 2H,
Ar-H, J= 4 Hz), 7.06 (s, 2H, NH2), 6.82–6.83 (d, 2H, Ar-H,
J= 4 Hz), 6.76–6.77 (d, 1H, Ar-H, J= 4 Hz), 6.87–6.88 (d,
1H, Ar-H, J= 4 Hz), 7.04–7.05 (m, 1H, Ar-H), 7.22–7.23 (d,
1H, Ar-H), 7.69 (s, 1H, NH), 8.36–8.37 (d, 1H, Ar-H,
J= 4 Hz), 8.90 (s, 1H, Ar-H). Anal. Calcd: C23H17N7O8S2:
C, 47.34; H, 2.94; N, 16.80; O, 21.93; Found: C, 47.30; H,
2.96; N, 16.76; O, 21.89; MS: m/z.
2.1.9.1.7. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(40-hydroxyphenyl)-pyrimidine-5-carbox-
amide (Eg). Yield (70%), mp 148–150 C; 1H NMR (CDCl3)
d= 4.79 (s, 2H, NH2), 5.06 (s, 1H, OH), 6.43–6.44 (d, 2H,
Ar-H, J= 4 Hz), 6.78–6.79 (d, 1H, Ar-H, J= 4 Hz), 6.83–
6.85 (m, 4H, Ar-H), 7.06–7.07 (m, 2H, Ar-H), 7.08 (s, 2H,
NH2), 7.23–7.24 (d, 1H, Ar-H, J= 4 Hz), 7.68 (s, 1H, NH),
8.37–8.38 (d, 1H, Ar-H, J= 4 Hz), 8.88 (s, 1H, Ar-H). Anal.
Calcd: C23H17N7O8S2: C, 47.34; H, 2.94; N, 16.80; O, 21.93;
Found: C, 47.28; H, 2.93; N, 16.78; O, 21.90; MS: m/z.
2.1.9.1.8. 2-[(20,40-Dinitrophenyl)thio]-4-(p-aminophenyl-
sulphonylamino)-6-(40-nitrophenyl)-pyrimidine (Eh). Yield
(48%), mp 138–140 C; 1H NMR (CDCl3) d= 4.77 (s, 2H,
NH2), 6.43–6.44 (d, 2H, Ar-H, J= 4 Hz), 6.87–6.88 (m, 2H,
Ar-H) 7.06 (s, 2H, NH2), 7.23–7.24 (d, 1H, Ar-H, J= 4 Hz),
7.68 (s, 1H, NH), 7.82–7.83 (m, 2H, Ar-H), 8.26–8.27 (m,
2H, Ar-H), 8.38–8.39 (d, 1H, Ar-H, J= 4 Hz), 8.89 (s, 1H,
Ar-H). Anal. Calcd: C23H16N8O9S2: C, 45.10; H, 2.63; N,
18.29; O, 23.51; Found: C, 45.06; H, 2.67; N, 18.24; O,
23.49; MS: m/z.
2.1.9.2. Preparation of 2-[(20,40-dinitrophenyl)sulphonyl]-4-(p-
aminophenylsulphonylamino)-6-(aryl)-pyrimidine-5-carboxam-
ide (Fa–h). A mixture of 2-[(2
0,40-dinitrophenyl)thio]-4-(p-ami
nophenylsulphonylamino)-6-(aryl)-pyrimidine-5-carboxamide
(0.01 M) was dissolved in 20 ml of gla. acetic acid and added
12 ml of hydrogen peroxide and then kept for 48 h. at room
temperature. The content was poured into ice cold water and
ﬁltered. The product was isolated and crystallized from
ethanol.
2.1.9.2.1. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-arylpyrimidine-5-carboxamide (Fa).
Yield (46%), mp 107–109 C; 1H NMR (CDCl3) d= 4.72 (s,
2H, NH2), 6.42–6.43 (m, 2H, Ar-H), 7.05 (s, 2H, NH2),
7.21–7.22 (d, 1H, Ar-H, J= 4 Hz), 7.37–7.39 (m, 2H, Ar-H),
7.43–7.44 (d, 2H, Ar-H, J= 4 Hz), 7.48–7.49 (m, 2H, Ar-H),
7.67 (s, 1H, NH), 8.46–8.47 (d, 1H, Ar-H, J= 4 Hz), 8.90
(d, 1H, Ar-H, J= 4 Hz), 9.37 (s, 1H, Ar-H); 13C NMR (d)
172.4, 168.4, 168.2, 165.9, 154.4, 151.4, 147.2, 139.9, 133.0,Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluat
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2130.2, 129.4, 128.9, 128.3, 128.2, 127.6, 119.6, 116.7, 116.3;
Anal. Calcd C23H17N7O9S2: C, 46.08; H, 2.86; N, 16.35; O,
24.02; Found: C, 46.06; H, 2.83; N, 16.37; O, 24.04; MS: m/z
599.
2.1.9.2.2. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-(20-chlorophenyl)-pyrimidine-5-car-
boxamide (Fb). Yield (60%), mp 118–120 C; 1H NMR
(CDCl3) d= 4.73 (s, 2H, NH2), 6.62–6.63 (m, 2H, Ar-H),
7.08 (s, 2H, NH2), 7.17–7.18 (d, 2H, Ar-H, J= 4 Hz), 7.31–
7.32 (d, 1H, Ar-H, J= 4 Hz) 7.39–7.40 (d, 1H, Ar-H,
J= 4 Hz), 7.67 (s, 1H, NH), 7.66–7.67 (d, 2H, Ar-H,
J= 4 Hz), 8.41–8.42 (d, 1H, Ar-H, J= 4 Hz), 8.85 (d, 1H,
Ar-H, J= 4 Hz), 9.42 (s, 1H, Ar-H); 13C NMR (d) 172.5,
168.5, 168.2, 165.8, 154.5, 151.5, 147.1, 139.8, 132.3, 130.3,
130.1, 128.9, 129.6, 129.3, 128.7, 128.4, 127.5, 116.4, 116.2;
Anal. Calcd: C23H16ClN7O9S2: C, 43.57; H, 2.54; N, 15.46;
O, 22.71; Found: C, 43.54; H, 2.53; N, 15.44; O, 22.73; MS:
m/z 634.
2.1.9.2.3. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-(40-chlorophenyl)-pyrimidine-5-car-
boxamide (Fc). Yield (55%), mp 125–127 C; 1H NMR
(CDCl3) d= 4.74 (s, 2H, NH2), 6.73–6.74 (d, 2H, Ar-H),
7.09 (s, 2H, NH2), 7.34–7.35 (d, 2H, Ar-H, J= 4 Hz), 7.39–
7.40 (d, 2H, Ar-H, J= 4 Hz), 7.57 (s, 1H, NH), 7.65–7.66
(d, 2H, Ar-H, J= 4 Hz), 8.43–8.44 (d, 1H, Ar-H, J= 4 Hz),
8.88–8.89 (d, 1H, Ar-H, J= 4 Hz), 9.43 (s, 1H, Ar-H); 13C
NMR (d) 172.4, 168.5, 168.3, 165.7, 154.6, 151.4, 147.2,
139.7, 134.3, 131.3, 130.0, 129.8, 129.5, 128.8, 128.3, 128.0,
116.5, 116.3; Anal. Calcd: C23H16ClN7O9S2: C, 43.57; H,
2.54; N, 15.46; O, 22.71; Found: C, 43.54; H, 2.53; N, 15.44;
O, 22.73; MS: m/z 634.
2.1.9.2.4. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-(30-bromophenyl)-pyrimidine-5-car-
boxamide (Fd). Yield (49%), mp 111–113 C; 1H NMR
(CDCl3) d= 4.76 (s, 2H, NH2), 6.73–6.74 (d, 2H, Ar-H,
J= 4 Hz) 7.09 (s, 2H, NH2), 7.21–7.22 (m, 2H, Ar-H), 7.39–
7.40 (d, 2H, Ar-H, J= 4 Hz), 7.43–7.44 (d, 2H, Ar-H,
J= 4 Hz), 7.64 (s, 1H, Ar-H), 7.67–7.68 (d, 2H, Ar-H,
J= 4 Hz) 7.70 (s, 1H, NH), 8.43–8.44 (d, 1H, Ar-H,
J= 4 Hz), 8.81 (d, 1H, Ar-H, J= 4 Hz), 9.42 (s, 1H, Ar-H);
13C NMR (d) 172.3, 168.6, 168.4, 165.6, 154.5, 151.3, 147.2,
139.6, 135.3, 133.2, 131.8, 131.6, 130.0, 129.8, 128.3, 128.1,
126.6, 123.5, 119.8, 116.7, 116.4; Anal. Calcd:
C23H16BrN7O9S2: C, 40.72; H, 2.38; N, 14.45; O, 21.22;
Found: C, 40.74; H, 2.34; N, 14.42; O, 21.23; MS: m/z 678.
2.1.9.2.5. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-
aminophenylsulphonylamino)-6-(40-methoxyphenyl)-pyrim-
idine-5-carboxamide (Fe). Yield (42%), mp 104–106 C; 1H
NMR (CDCl3) d= 3.75 (s, 3H, OCH3), 4.75 (s, 2H, NH2),
6.67–6.68 (d, 2H, Ar-H, J= 4 Hz), 6.83–6.84 (d, 2H, Ar-H,
J= 4 Hz), 7.08 (s, 2H, NH2), 7.32–7.33 (d, 1H, Ar-H), 7.67–
7.68 (d, 2H, Ar-H, J= 4 Hz), 7.73 (s, 1H, NH), 8.46–8.47
(d, 1H, Ar-H, J= 4 Hz), 8.87 (d, 1H, Ar-H, J= 4 Hz), 9.42
(s, 1H, Ar-H); 13C NMR (d) 172.4, 168.7, 168.2, 165.7,
160.6, 154.4, 151.4, 147.3, 139.5, 130.2, 128.6, 128.4, 128.1,
116.7, 116.5, 114.9, 55.7; Anal. Calcd: C24H19N7O10S2: C,
45.79; H, 3.04; N, 15.57; O, 25.41; Found: C, 45.77; H, 3.06;
N, 15.55; O, 25.45; MS: m/z 629.
2.1.9.2.6. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-(20-hydroxyphenyl)-pyrimidine-5-car-
boxamide (Ff). Yield (61%), mp 113–115 C; 1H NMR
(CDCl3) d= 4.76 (s, 2H, NH2), 5.15 (s, 1H, OH), 6.76–6.77ion of pyrimidinyl sulphonamide derivatives as promising class of antitubercular
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6.87–6.88 (d, 1H, Ar-H, J= 4 Hz), 7.04–7.05 (m, 1H, Ar-H),
7.06 (s, 2H, NH2), 7.22–7.23 (d, 1H, Ar-H), 7.68 (s, 1H,
NH), 8.44–8.45 (d, 1H, Ar-H, J= 4 Hz), 8.89 (d, 1H, Ar-H,
J= 4 Hz), 9.42 (s, 1H, Ar-H); Anal. Calcd: C23H17N7O10S2:
C, 44.88; H, 2.78; N, 15.93; O, 25.99; Found: C, 44.85; H,
2.76; N, 15.96; O, 25.98; MS: m/z 615.
2.1.9.2.7. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-(40-hydroxyphenyl)-pyrimidine-5-car-
boxamide (Fg). Yield (70%), mp 148–150 C; 1H NMR
(CDCl3) d= 4.79 (s, 2H, NH2), 5.06 (s, 1H, OH), 6.43–6.44
(d, 2H, Ar-H, J= 4 Hz), 6.78–6.79 (d, 1H, Ar-H, J= 4 Hz),
6.83–6.85 (m, 4H, Ar-H), 7.06–7.07 (m, 2H, Ar-H), 7.08 (s,Table 1 In vitro antitubercular screening data of pyridines Aa-h to
Sr. No. Molecule No. R % Inhibition
Ad 305,302 4-Br 51
Ah 305,306 4-OCH3 70
Ba 305,307 H 70
Bb 305,308 2-Cl 56
Bc 305,309 4-Cl 92
Bd 305,310 3-Br 86
Be 305,311 4-OCH3 79
Bf 305,312 2-OH 53
Bg 305,313 4-OH 72
Bh 305,314 4-NO2 46
Cb 305,316 2-Cl 99
Cc 305,317 4-Cl 44
Cd 305,318 3-Br 56
Ce 305,319 4-OCH3 87
Cf 305,320 2-OH 57
Cg 305,321 4-OH 40
Ch 305,322 4-NO2 51
Da 305,323 H 87
Db 305,324 2-Cl 100
Dc 305,325 4-Cl 84
Dd 305,326 3-Br 63
De 305,327 4-OCH3 87
Df 305,328 2-OH 56
Dg 305,329 4-OH 36
Dh 305,330 4-NO2 82
Ea 305,331 H 73
Eb 305,332 2-Cl 13
Ec 305,333 4-Cl 07
Ed 305,334 3-Br 32
Ee 305,335 4-OCH3 42
Ef 305,336 2-OH 34
Eg 305,337 4-OH 100
Eh 305,338 4-NO2 41
Fa 305,339 H 59
Fb 305,340 2-Cl 100
Fc 305,341 4-Cl 44
Fd 305,342 3-Br 25
Fe 305,343 4-Br 23
Fg 305,345 4-OH 45
Fh 305,346 4-NO2 29
INH – – –
n.d.: Not determined.
a Minimum inhibitory concentration against H37Rv strain of M. tuberc
b Measurement of cytotoxicity in VERO cells: 50% inhibitory concentr
c Selectivity index (in vitro): IC50 in VERO cells/MIC against M. tuber
d Data from TAACF.
e The activity criterion for this assay is a SI > 10.
Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluati
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.22H, NH2), 7.23–7.24 (d, 1H, Ar-H, J= 4 Hz), 7.68 (s, 1H,
NH), 8.37–8.38 (d, 1H, Ar-H, J= 4 Hz), 8.88 (s, 1H, Ar-H).
Anal. Calcd: C23H17N7O8S2: C, 47.34; H, 2.94; N, 16.80;
O, 21.93; Found: C, 47.28; H, 2.93; N, 16.78; O, 21.90;
MS: m/z.
2.1.9.2.8. 2-[(20,40-Dinitrophenyl)sulphonyl]-4-(p-amino-
phenylsulphonylamino)-6-(40-nitrophenyl)-pyrimidine (Fh).
Yield (48%), mp 138–140 C; 1H NMR (CDCl3) d= 4.77 (s,
2H, NH2), 6.43–6.44 (d, 2H, Ar-H, J= 4 Hz), 6.87–6.88 (m,
2H, Ar-H) 7.06 (s, 2H, NH2), 7.23–7.24 (d, 1H, Ar-H,
J= 4 Hz), 7.68 (s, 1H, NH), 7.82–7.83 (m, 2H, Ar-H), 8.26–
8.27 (m, 2H, Ar-H), 8.38–8.39 (d, 1H, Ar-H, J= 4 Hz), 8.89
(s, 1H, Ar-H). Anal. Calcd: C23H16N8O9S2: C, 45.10; H,Fa-h.
MICa lg/mL IC50
b VERO cells SIc (SI = IC50/MIC)
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
<6.25 0.793 0.126
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 8.83 2.82
>6.25 n.d. n.d.
>6.25 n.d. n.d.
<6.25 9.213 1.47
>6.25 n.d n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
<6.25 n.d. n.d.
0.02 13.963 2.234
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
<6.25 0.748 0.119
>6.25 n.d. n.d.
>6.25 n.d. n.d.
0.02 79.555 12.728
>6.25 n.d n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
>6.25 n.d. n.d.
0.03d >1000 >40,000e
ulosis (lg/mL).
ations (lg/mL).
culosis.
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10 N.H. Bhuva et al.2.63; N, 18.29; O, 23.51; Found: C, 45.06; H, 2.67; N, 18.24; O,
23.49; MS: m/z.
3. Antimycobacterial activity
All the newly synthesized compounds Aa–Fh were initially
screened for their in vitro antimycobacterial activity at
6.25 lg/mL against Mycobacterium tuberculosis H37Rv strain
by the Tuberculosis Antimicrobial Acquisition and
Coordinating Facility (TAACF) in BACTEC 12B medium
using the microplate alamar blue assay [15]. The results of
the antitubercular studies are presented in Table 1.
Compounds exhibiting P90% inhibition in the initial screening
were tested at below 6.25 lg/mL using 2-fold dilution to deter-
mine the actual MIC. In preliminary screening, ﬁve com-
pounds (Bc, Cb, Db, Eg and Fb) inhibited Mtb with 90–100%.
In the secondary level, two compounds (Fb, Db) inhibited
Mtb with MIC of <1 lg/mL and three compounds (Eg, Bc,
Cb) with MIC of <3 lg/mL when compared to isoniazid
(MIC: 0.03 lg/mL). Among all the compounds, 2-[(20,40-dini
trophenyl)sulphonyl]-4-(p-aminophenylsulphonylamino)-6-(20-
chlorophenyl)-pyrimidine-5-carboxamide (Fb) was found to be
the most active compound in vitro with MIC of <0.02 lg/mL
against Mtb. Moreover among these compound 2-hydrazino-
4-(p-aminophenylsulphonylamino)-6-(20-chlorophenyl)-pyrimi
dine-5-carboxamide Db also gives promising activity with MIC
of <0.02 lg/mL against Mtb. The activity was considerably
affected by substitutions at the phenyl ring of the pyrimidine
nucleus. It was observed that in a group of compounds having
electron-withdrawing halogen group on the ortho and para
positions and hydroxy at para position of the phenyl ring were
inﬂuencing the antitubercular activity signiﬁcantly (Bc, Cb, Db,
Eg and Fb). Having identiﬁed a good number of active antimy-
cobacterial compounds, the next step was to examine the tox-
icity of the drug candidates. Compounds exhibiting relatively
low MICs were tested for cytotoxicity (IC50) in VERO cells
and a selectivity index (SI), deﬁned as IC50: MIC was calcu-
lated. The compounds Bc and Eg were somewhat more toxic
than Cb, Db, and Fb. Generally compounds with an
MIC 6 6.25 lg/mL and SIP 10 are interesting compounds,
and an MIC 6 1 lg/mL in a novel compound class may be
considered an excellent lead, [16] which makes 2-[(20,40-dinitro
phenyl)sulphonyl]-4-(p-aminophenylsulphonylamino)-6-(20-chl
orophenyl)-pyrimidine-5-carboxamide (Fb) very promising
antimycobacterial compound. In conclusion, we have conve-
niently synthesized a series of novel pyrimidinyl sulphonamide
derivatives bearing a pyrimidine nucleus and evaluated their
in vitro antitubercular activity with anticipation of generating
new structural leads. The results indicate that the preparative
pathway elaborated by us to the novel pyrimidinyl sulphona-
mide having a pyrimidine nucleus may open a relatively facile
route to a new class of antitubercular compounds.
4. Results and discussion
4.1. Chemistry
The synthetic route for the preparation of pyrimidine deriva-
tives (Aa–h to Fa–h) is summarized in Scheme 1. Various substi-
tuted aromatic aldehyde with a range of electron withdrawing
and electron donating substituents, viz., -H, 2-Cl, 4-Cl, 3-Br, 4-Please cite this article in press as: N.H. Bhuva et al., Synthesis and biological evaluat
agents, Journal of Saudi Chemical Society (2015), http://dx.doi.org/10.1016/j.jscs.2OCH3, 2-OH, 4-OH and 4-NO2 reacted with malononitrile
and thiourea by multicomponent reaction is of Biginelli reac-
tion affords dihydropyrimidine (1) which on reaction with
Con. H2SO4 oxidizes to pyrimidine (2). All the pyrimidine
derivatives (Aa–h to Fa–h) were synthesized by coupling reaction
of (2) with p-acetamidophenylsulphonylchloride. The yields of
the products were obtained in the range of 45–76%. Designed
series of molecules (Table 1) were characterized by 1H NMR,
13C NMR, and Mass spectrometry techniques before evaluat-
ing for antimycobacterial activity.
5. Conclusions
In the present paper, we report the synthesis, spectral studies
and antimycobacterial activity of various pyrimidine deriva-
tives. The high bioactivity of these compounds makes them
suitable tools for additional in vitro and in vivo evaluations,
in order to develop a new class of antimycobacterial drugs
or prodrugs with potential antitubercular activity in the treat-
ment of tuberculosis (TB). Further studies and modiﬁcation in
this area are in progress in our laboratory.
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